Celularity (NASDAQ:CELU) Coverage Initiated by Analysts at WBB Securities

Key Points

• WBB Securities has initiated coverage on Celularity (NASDAQ:CELU) with a "speculative buy" rating and a price target of $6.00, suggesting a potential upside of 60% from the current trading price.
• Despite WBB's positive outlook, Wall Street Zen recently downgraded Celularity to a "sell" rating, indicating mixed sentiment among analysts.
• Institutional investors have shown interest in Celularity, with Bank of America Corp DE significantly increasing its position by 1,538.1% in the second quarter of this year.

Stock analysts at WBB Securities began coverage on shares of Celularity (NASDAQ:CELU - Get Free Report) in a research report issued on Monday, MarketBeat Ratings reports. The brokerage set a "moderate buy" rating and a $6.00 price target on the stock. WBB Securities' price target would suggest a potential upside of 63.71% from the stock's current price.

Separately, Wall Street Zen raised shares of Celularity to a "sell" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $6.00.

Celularity Stock Up 1.5%

Shares of CELU traded up $0.0550 during mid-day trading on Monday, hitting $3.6650. The company's stock had a trading volume of 2,820 shares, compared to its average volume of 170,080. The company's 50-day moving average is $2.59 and its 200-day moving average is $2.06. Celularity has a 52-week low of $1.00 and a 52-week high of $5.22. The firm has a market capitalization of $87.78 million, a price-to-earnings ratio of -1.38 and a beta of 0.79. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new position in Celularity during the 1st quarter valued at approximately $34,000. XTX Topco Ltd increased its stake in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after purchasing an additional 11,057 shares in the last quarter. Bank of America Corp DE increased its stake in Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after purchasing an additional 35,023 shares in the last quarter. Two Sigma Investments LP acquired a new position in Celularity during the 4th quarter valued at approximately $93,000. Finally, Valmark Advisers Inc. acquired a new stake in shares of Celularity in the second quarter worth $98,000. Institutional investors and hedge funds own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.